Atlas Trials

Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Clinical trial NCT03691376 · TERMINATED

Trial details

NCT number
NCT03691376
Sponsor
Roswell Park Cancer Institute
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal CarcinomaPlatinum-Sensitive Fallopian Tube CarcinomaPlatinum-Sensitive Ovarian CarcinomaPlatinum-Sensitive Primary Peritoneal CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaRefractory Fallopian Tube CarcinomaRefractory Ovarian CarcinomaRefractory Primary Peritoneal Carcinoma
Start date
2019-03-08
Primary completion
2021-01-30
Enrollment
4

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.